Despite a daily loss of 3.9% and a 3-month loss of 3.4%, Repligen Corp (NASDAQ:RGEN) shows a promising Earnings Per Share (EPS) of 2.42. This raises a compelling question: Is the stock significantly undervalued? Repligen Corp is a leading life sciences company with a global presence. It is renowned for developing and commercializing innovative bioprocessing...
RGEN I had plans to post before but now I want to update this plan separately because it looks better than before. - Cup and Handle pattern (with the right-hand Gap acts as the handle). - Confirm " symmetrical triangle " pattern above the Cup. Rgen buy : $155 Rgen target : $180+ Stop loss : $150 Wish you a good deal !
RGEN confirmed to break out of Coc, with the appearance of Gap on the right instead of the handle (Gap is big support) so you can understand this is the "Cup and Handle" pattern . RGEN buy : $147 +- 0,5 RGEN target : $180 +-1 Stop loss : 10% Wish you good deals!
RGEN: Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. RGEN as a mid-cap is new...